Logotipo Dedalus   Logotipo ABCD
                         
Identificação       Preferências   Catálogos   Fale Conosco   Encerrar Sessão  
Buscas   Resultados   Buscas Anteriores   Meus Docs.   Histórico   Vocabulário   Ajuda
 
  Adicionar Reg. Meus Docs.  |  Localizar  |  Salvar / E-mail  

Registro Completo

Escolher formato: Padrão Ficha Formato Reduzido Nomes MARC Campos MARC
No. Registro   002396511
Tipo de material   ARTIGO DE PERIODICO - INTERNACIONAL
Cód. publicação   Link10.1097/RLU.0b013e3182816717 DOI
Entrada Principal   LinkWillegaignon, José S (*)
Título   LinkRadioiodine Therapy for Graves Disease : Thyroid Absorbed Dose of 300 Gy—Tuning the Target for Therapy Planning.
Imprenta   Philadelphia, 2013.
Descrição   p. 231-236.
Idioma   Inglês
Nota   Disponível em: http://journals.lww.com/nuclearmed/toc/2013/04000
Assunto   LinkDOENÇA DE GRAVES (CINTILOGRAFIA;DIAGNÓSTICO)
  LinkSEGUIMENTOS
  LinkRADIOMETRIA
  LinkRADIOIMUNOENSAIO (USO TERAPÊUTICO)
  LinkDOSIMETRIA
  LinkHIPERTIREOIDISMO (USO TERAPÊUTICO)
Autor Secundário   LinkSapienza, Marcelo (*)
  LinkBuchpiguel, Carlos
Fonte   LinkIn: Clinical Nuclear Medicine, Philadelphia, v. 38, n. 4, p. 231-236, 2013, ISSN: 0363-9762
Localiz.Eletrônica    "Clicar" sobre o botão para acesso ao Currículo Lattes de Carlos A. Buchpiguel 
   "Clicar" sobre o botão para acesso ao texto online 
Resumo/Outros   Purposes: Based on the committed thyroid absorbed dose, the aim was to compare the efficiency of 131I therapy against Graves disease (GD) within 1 year after treatment and, by exploring the dose-response relationship, indicate an absorbed dose to be targeted into patient therapeutic planning. Methods: Thyroid-absorbed doses were calculated to 196 patients with GD by applying Medical Internal Radiation Dose formalism and taking into account administered 131I activity, thyroid radioiodine uptake, effective half-life, and gland tissue mass. Statistical analysis was applied to assess the relationship between absorbed doses and the patient’s clinical response. Results: Overall, successful therapy was achieved in 167 patients, whereas in 29 the disease persisted, even though 64.8% and 89.3% of all the treated patients had received, respectively, thyroid absorbed dose and activity superior to 300 Gy and 11.1 MBq/g (300 KCi/g) of thyroid tissue. Among those in whom the disease persisted, 24 (83%) had a 6- to 24-hour 131I uptake ratio equal or superior to 0.9, whereas only 5 (17%) presented a lower ratio. According to statistical analysis, there was no difference in cure rate between the groups that received 300 Gy or less and that which received more (84.1% vs 85.8%, P = 0.8336). Conclusions: A thyroid absorbed dose of 300 Gy is plausible as a targeted therapeutic dose in GD therapy planning, because statistical analysis has proven there to be no advantage in treating patients with doses above this level. On the other hand, numerous efforts should be made to develop an optimized and easily applicable protocol of patient-specific dosimetry and to provide data that show its clinical impact on patient management
 
Acervo Geral   Todos os itens
Itens na Biblioteca   FM-Fac. MedicinaLibrary Info
Unidade USP   FM -- FAC DE MEDICINA

Escolher formato: Padrão Ficha Formato Reduzido Nomes MARC Campos MARC


Encerrar Sessão - Preferências - Fale Conosco - Ajuda - Ex Libris
Buscas - Resultados - Buscas Anteriores - Catálogos